Src inhibitor dasatinib, FDA-approved compound for the treatment of chronic myeloid leukemia, was found to suppress resistance of breast cancer cells to endocrine therapy [107,108] and to doxorubicin [109]. This evidence concerns the gene SRC and chronic myelogenous leukemia, BCR-ABL1 positive.